Overview


According to FutureWise analysis, the market for Allogeneic Stem Cell Transplantation is expected to grow with a CAGR of 7.90% over the forecast period 2024-2032, and reach a market value of US$ 7.17 billion by 2031.

Allogeneic stem cell transplantation (also known as allogeneic SCT or allo-SCT) is a medical procedure in which stem cells are transferred from a healthy donor to a recipient who needs replacement or repair of damaged cells. These stem cells can be derived from bone marrow, peripheral blood, or cord blood. Allogeneic SCT is used to treat various conditions, including certain types of cancers (such as leukemia, lymphoma, and multiple myeloma) and non-malignant disorders (like aplastic anemia, severe combined immunodeficiency, and certain metabolic disorders). In allogeneic SCT, the donor and recipient are not the same person. The donor and recipient are typically related (such as a sibling) or unrelated but immunologically matched. The degree of matching is crucial to reduce the risk of graft-versus-host disease (GVHD), where the donor's immune cells attack the recipient's tissues.

The category of allogeneic stem cell transplantation is based on the type of cells used. For instance, stem cell type such as Allogeneic Mesenchymal Stem Cells (MSCs) are derived from the bone marrow, adipose tissue, or other sources of a healthy donor. These cells have shown remarkable potential in modulating the immune response, relieving inflammation, and promoting tissue repair. Allogeneic MSCs have been investigated as a potential therapy for conditions such as graft-versus-host disease (GVHD), autoimmune disorders, and certain inflammatory conditions. Another important cell type is Allogeneic Hematopoietic Stem Cells (HSCs). These stem cells, primarily sourced from bone marrow or peripheral blood, can differentiate into various types of blood cells, such as platelets, RBC, and WBC. Allo-SCT using HSCs is a cornerstone treatment for hematologic malignancies like leukemia, lymphoma, and myeloma. It allows for the replacement of cancerous cells with healthy, functioning blood cells.

FutureWise Market Research has published a report that provides an insightful analysis allogeneic stem cell transplantation market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. According to the analysis conducted by FutureWise research analysts allogeneic stem cell transplantation market estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Celgene Corporation
  • Mesoblast Ltd.
  • Pluristem Therapeutics Inc.
  • MEDIPOST Co., Ltd.
  • Takeda Pharmaceutical Company Limited
  • Astellas Pharma Inc.
  • Cellular Biomedicine Group, Inc.
  • Biosolution Co., Ltd.
  • StemCell Technologies Inc.
  • Caladrius Biosciences, Inc.
  • TiGenix N.V.
  • ViaCord
  • Vericel Corporation
  • Regen Biopharma Inc.
  • Gamida Cell Ltd.
  • Histogenics Corporation
  • BrainStorm Cell Therapeutics Inc.
  • Lineage Cell Therapeutics, Inc.

(Note: The list of the major players will be updated with the latest market scenario and trends)

The growing incidence of diseases like leukemia, lymphoma, and other blood-related disorders is a pivotal driver for the allogeneic stem cell transplantation market. As these conditions become more prevalent, the demand for effective treatment options increases. Allogeneic stem cell transplantation emerges as a crucial lifeline for patients who have exhausted conventional therapies, positioning it as a last-resort intervention. This critical need propels the market forward as healthcare providers increasingly turn to this advanced procedure to offer hope and potentially life-saving treatment for individuals facing these severe and often life-threatening hematological disorders. Moreover, continuous progress in transplant techniques, characterized by enhanced matching algorithms, decreased toxicity in conditioning regimens, and improved post-transplant care is revolutionizing the field. These advancements not only boost the success rates of transplantation but also expand the pool of eligible recipients, further driving the demand for allogeneic stem cell transplantation as a preferred treatment approach. Also, the rising aging population is anticipated to propel the growth of the allogeneic stem cell transplantation market. With a growing number of individuals entering advanced age brackets, the likelihood of developing diseases that may necessitate stem cell transplantation, such as leukemia, lymphoma, and other blood-related disorders, significantly rises. Thus, the expanding elderly population is a substantial driver for the continuous growth and applicability of the allogeneic stem cell transplantation market. However, the complexity and high costs of allogeneic stem cell transplantation present a substantial restraint in its widespread adoption. This complex procedure involves intricately coordinated steps, from particular donor selection to rigorous conditioning, transplantation, and comprehensive post-transplant care. Each phase demands specialized expertise, advanced medical technology, and significant resources. Consequently, the extensive expenses incurred throughout the entire process may serve as a formidable barrier, limiting accessibility to this potentially life-saving treatment option for a significant part of the population, particularly in regions with limited healthcare resources or individuals without adequate insurance coverage, thus impeding the market growth.

By Source 

  • Bone Marrow
  • Peripheral Blood
  • Umbilical Cord Blood
  • Adipose Tissue
  • Dental Pulp
  • Others

By Application

  • Cancer
  • Autoimmune Diseases
  • Blood Disorders
  • Cardiac Disorders
  • Neurological Disorders
  • Diabetes
  • Others

By Cell Type

  • Allogeneic MSCs
  • Allogeneic HSCs
  • Others

By End User

  • Hospitals
  • Research Institutes
  • Specialty Clinics
  • Others

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. This is attributed to factors like the increasing prevalence of chronic diseases, advances in stem cell research, the rise in demand for personalized medicines, the increasing geriatric population, and the well-established healthcare infrastructure in the region, which is projected to accelerate the market expansion over the forecast period. Moreover, increasing inorganic growth strategies, such as acquisitions by market players to extend their product portfolio, growing awareness, product launches, and increases in investment in regenerative medicine are also boosting the market growth in the area. For instance, in June 2023, Kindred Group plc, a company that offers online services, launched a new campaign with Matchis, the Dutch Centre for Stem Cell Donors, to generate more awareness for stem cell transplantation and the shortage of donors.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Allogeneic Stem Cell Transplantation Market By Source, By Application, By Cell Type, By End User and By Region
  • To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
  • To evaluate and forecast micro-markets and the overall market
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To record and evaluate competitive landscape, mapping- product launches, technological advancements, mergers and expansions

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.  Market Introduction
    •   1. Objectives of the Study 
        2. Market Definition 
        3. Market Scope 
           3.1. Years Considered for the Study
           3.2. Market Covered
        4. Currency 
        5. Limitations 
        6. Stakeholders 

  • 2.  Research Methodology
    •   1. Research Data 
           1.1. Secondary Data
              1.1.1. Key Data from Secondary Sources
           1.2 Primary Data
              1.2.1. Key Data from Primary Sources
        3. Market Size Estimation 
        4. Market Breakdown and Data Triangulation 
        5. Assumptions for the Study 

  • 3.  Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights

  • 4.  Allogeneic Stem Cell Transplantation Market Variables, Trends & Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Application Overview
        6. Regulatory Framework
           6.1. Reimbursement Framework
           6.2. Standards and Compliances

  • 5.  Market Overview
    •   1. Market Dynamics
           1.1. Market Driver Analysis
              1.1.1. Increasing focus of Allogeneic Stem Cell Transplantation Market Companies on Brand Protection
              1.1.2. Untapped Opportunities in Emerging Regions
           1.2. Market Restraint Analysis
              1.2.1. High Cost Associated with Implementation of Predictive Analysis
           1.3. Industry Challenges
              1.3.1. Presence of Ambiguous Regulatory Framework

  • 6.  Allogeneic Stem Cell Transplantation Market Analysis Tools
    •   1. Industry Analysis - Porter’s
           1.1. Supplier Power
           1.2. Buyer Power
           1.3. Substitution Threat
           1.4. Threat from New Entrants
           1.5. Competitive Rivalry
        2. Pestel Analysis
           2.1. Political Landscape
           2.2. Environmental Landscape
           2.3. Social Landscape
           2.4. Application Landscape
           2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
           3.1. Joint Ventures
           3.2. Mergers and Acquisitions
           3.3. Licensing and Partnership
           3.4. Application Collaborations
           3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies

  • 7.  Allogeneic Stem Cell Transplantation Market, By Source Historical Analysis and Forecast 2024-2032 (USD Million)
    •  1. Bone Marrow
       2. Peripheral Blood
       3. Umbilical Cord Blood
       4. Adipose Tissue
       5. Dental Pulp
       6. Others

  • 8.  Allogeneic Stem Cell Transplantation Market, By Application Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Cancer
        2. Autoimmune Diseases
        3. Blood Disorders
        4. Cardiac Disorders
        5. Neurological Disorders
        6. Diabetes
        7. Others

  • 9.  Allogeneic Stem Cell Transplantation Market, By Cell Type Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Allogeneic MSCs
        2. Allogeneic HSCs
        3. Others

  • 10.  Allogeneic Stem Cell Transplantation Market, By End User Historical Analysis and Forecast 2024-2032 (USD Million)
    •   1. Hospitals
        2. Research Institutes
        3. Specialty Clinics
        4. Others

  • 11.  North America Allogeneic Stem Cell Transplantation Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. U.S.A
           2.2. Canada
           2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2024-2032

  • 12.  Latin America Allogeneic Stem Cell Transplantation Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Brazil
           2.2. Venezuela
           2.3. Argentina
           2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2024-2032

  • 13.  Europe Allogeneic Stem Cell Transplantation Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Germany
           2.2. U.K
           2.3. France
           2.4. Italy
           2.5. Spain
           2.6. Russia
           2.7. Poland
           2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2024-2032

  • 14.  Asia Pacific Allogeneic Stem Cell Transplantation Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. Japan
           2.2. China
           2.3. India
           2.4. Australia and New Zealand
           2.5. ASEAN
           2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2024-2032  

  • 15.  Middle East and Africa Market Analysis 2018-2023 and Forecast 2024-2032 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2018-2023
           2.1. GCC
           2.2. Israel
           2.3. South Africa
           2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2024-2032

  • 16.  Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix

  • 17.  Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Celgene Corporation
           1.1. Company Overview
           1.2. Product Portfolio
           1.3. SWOT Analysis
           1.4. Financial Overview
           1.5. Strategic Overview
        2. Mesoblast Ltd.
           2.1. Company Overview
           2.2. Product Portfolio
           2.3. SWOT Analysis
           2.4. Financial Overview
           2.5. Strategic Overview
        3. Pluristem Therapeutics Inc.
           3.1. Company Overview
           3.2. Product Portfolio
           3.3. SWOT Analysis
           3.4. Financial Overview
           3.5. Strategic Overview
        4. MEDIPOST Co., Ltd.
           4.1. Company Overview
           4.2. Product Portfolio
           4.3. SWOT Analysis
           4.4. Financial Overview
           4.5. Strategic Overview
        5. Takeda Pharmaceutical Company Limited
           5.1. Company Overview
           5.2. Product Portfolio
           5.3. SWOT Analysis
           5.4. Financial Overview
           5.5. Strategic Overview
        6. Astellas Pharma Inc.
           6.1. Company Overview
           6.2. Product Portfolio
           6.3. SWOT Analysis
           6.4. Financial Overview
           6.5. Strategic Overview
        7. Cellular Biomedicine Group, Inc.
           7.1. Company Overview
           7.2. Product Portfolio
           7.3. SWOT Analysis
           7.4. Financial Overview
           7.5. Strategic Overview
        8. Biosolution Co., Ltd.
           8.1. Company Overview
           8.2. Product Portfolio
           8.3. SWOT Analysis
           8.4. Financial Overview
           8.5. Strategic Overview
        9. StemCell Technologies Inc.
           9.1. Company Overview
           9.2. Product Portfolio
           9.3. SWOT Analysis
           9.4. Financial Overview
           9.5. Strategic Overview
        10. Caladrius Biosciences, Inc.
           10.1. Company Overview
           10.2. Product Portfolio
           10.3. SWOT Analysis
           10.4. Financial Overview
           10.5. Strategic Overview
        11. TiGenix N.V.
           11.1. Company Overview
           11.2. Product Portfolio
           11.3. SWOT Analysis
           11.4. Financial Overview
           11.5. Strategic Overview
        12. ViaCord
           12.1. Company Overview
           12.2. Product Portfolio
           12.3. SWOT Analysis
           12.4. Financial Overview
           12.5. Strategic Overview
        13. Vericel Corporation
           13.1. Company Overview
           13.2. Product Portfolio
           13.3. SWOT Analysis
           13.4. Financial Overview
           13.5. Strategic Overview
        14. Regen Biopharma Inc.
           14.1. Company Overview
           14.2. Product Portfolio
           14.3. SWOT Analysis
           14.4. Financial Overview
           14.5. Strategic Overview
        15. Gamida Cell Ltd.
           15.1. Company Overview
           15.2. Product Portfolio
           15.3. SWOT Analysis
           15.4. Financial Overview
           15.5. Strategic Overview
        16. Histogenics Corporation
           16.1. Company Overview
           16.2. Product Portfolio
           16.3. SWOT Analysis
           16.4. Financial Overview
           16.5. Strategic Overview
        17. BrainStorm Cell Therapeutics Inc.
           17.1. Company Overview
           17.2. Product Portfolio
           17.3. SWOT Analysis
           17.4. Financial Overview
           17.5. Strategic Overview
        18. Lineage Cell Therapeutics, Inc.
           18.1. Company Overview
           18.2. Product Portfolio
           18.3. SWOT Analysis
           18.4. Financial Overview
           18.5. Strategic Overview

  • 18.  Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated
      by administrations
        5. The overall economic slowdown of the developing and developed nations

  • 19.  FutureWise SME Key Takeaway Points for Client
    •      

Partner

Our Clients